Moderna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 1.02%. Elsewhere, the Dow gained 0.4%, while the tech-heavy Nasdaq added 2.03%.Heading into today, shares of the biotechnology company had lost 0.36% over the past month, outpacing the Medical sector's loss of 5.2% and the S&P 500's loss of 3.15% in that time.Analysts and investors alike will be keeping a close eye on the performa ...

This ambitious biotech aims to launch 15 products over the coming five years.Moderna (MRNA -2.45%) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions of dollars in sales. But as demand for the vaccine declined, Moderna stock followed. Investors are worried about future growth since the vaccine is the biotech's only commercialized product.But things may be about to turn around for Moderna. The biotech company aims to bring as man ...

Moderna (MRNA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this biotechnology company have returned -0.4%, compared to the Zacks S&P 500 composite's -0.9% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Moderna falls in, has lost 7.5%. The key question now is: What could be the stock's future direction?While med ...

Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.74%. At the same time, the Dow lost 0.01%, and the tech-heavy Nasdaq gained 1.68%.Prior to today's trading, shares of the biotechnology company had gained 0.59% over the past month. This has outpaced the Medical sector's loss of 4.72% and lagged the S&P 500's gain of 0.8% in that time.The investment community will be paying close atte ...

Moderna on Thursday said it has paused plans to build a vaccine manufacturing site in Kenya after a steep drop in demand for its Covid vaccines.The biotech company said it has not received any vaccine orders for Africa since 2022 and has taken more than $1 billion in losses and write-downs related to the cancellation of previous orders from the continent.Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint. The company's business took a major h ...

Shares of Moderna (MRNA) rose 6.2% on Apr 9 after management announced encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in certain patients with head and neck cancer. The INT is being developed in collaboration with Merck (MRK) .This portion of the study evaluated the combination of mRNA-4157 and Merck’s blockbuster immuno-oncology drug Keytruda in patients with human papillomavirus negative (HPV-) head and neck squamous ...

Moderna (MRNA) shares ended the last trading session 6.2% higher at $111.60. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.2% loss over the past four weeks.Shares price rose after management reported encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in certain patients with head and neck cancer.This portion of the study evalua ...

Key TakeawaysModerna reported positive results of a small-sample trial of its experimental individualized cancer vaccine and Merck's Keytruda to treat those with head and neck cancers.The study found the combination boosted the immune response in patients.Moderna said research on using the treatment in a more advanced disease setting may be warranted. Moderna (MRNA) shares jumped Tuesday after the biotech firm reported positive results from a small trial involving those with head and neck cancers treated wi ...

Key TakeawaysThe S&P 500 edged up 0.1% on Tuesday, April 9, 2024, ahead of critical Consumer Price Index (CPI) data set to be released on Wednesday.Shares of Moderna soared after the firm's individualized cancer vaccine showed promise in treating patients with a certain type of head and neck cancer.Royal Caribbean shares moved lower amid a string of negative incidents for the cruise operator. Major U.S. equities made little headway in the session preceding the release of Consumer Price Index (CPI) report fo ...

Moderna Inc (NASDAQ: MRNA) popped as much as 10% on Tuesday after a Jefferies analyst made upbeat remarks on new data for its experimental vaccine for head and neck cancer.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.MRNA-4157 has potential beyond melanoma Copy link to section The biotech giant reported positive early-stage results for its MRNA-4157 in combination with Keytruda (Merck) as a treatment of head and neck cancer this week. Analysts at J ...